Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Universal Trial Number (UTN) | Other Identifier | U1111-1261-1912 | |
| 2020-005435-75 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.
Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cagrisema | Experimental | Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks. |
|
| Cagrilintide | Active Comparator | Participants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks. |
|
| Semaglutide | Active Comparator | Participants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks. |
|
| Placebo s.c. | Placebo Comparator | Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cagrilintide | Drug | Cagrilintide will be administered subcutaneously. |
|
| Measure | Description | Time Frame |
|---|---|---|
| CagriSema versus placebo: Relative change in body weight | Measured in percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction | Measured as count of participants | From baseline (week 0) to end of treatment (week 68) |
| Measure | Description | Time Frame |
|---|---|---|
| CagriSema versus placebo: Achievement of >= 20% weight reduction | Measured as count of participant | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Achievement of >= 25% weight reduction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency (dept. 2834) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Univ of Alabama Birmingham | Birmingham | Alabama | 35233 | United States | ||
| Velocity Clin Res Los Angeles |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41328546 | Derived | Verma S, Bottcher M, Brown P, Dicker D, Rubino D, Sbraccia P, Sharma AM, Smedegaard L, Sorrig R, Garvey WT. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 2026 Feb;83(2):e26055. doi: 10.1161/HYPERTENSIONAHA.125.26055. Epub 2025 Dec 2. | |
| 40544433 | Derived | Garvey WT, Bluher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietilainen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH; REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. |
Not provided
Not provided
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Semaglutide | Drug | Participants will recieve semaglutide subcutaneously. |
|
| Placebo cagrilintide | Drug | Participants will receive placebo matched to cagrilintide. |
|
| Placebo semaglutide | Drug | Participants will receive placebo matched to semaglutide. |
|
Measured as count of participant
| From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Achievement of >= 30% weight reduction | Measured as count of participant | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weight | Measured as percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Relative change in body weight | Measured as percentage (%) | From baseline (week 0) to week 8 |
| CagriSema versus placebo: Relative change in body weight | Measured as percentage (%) | From baseline (week 0) to week 20 |
| CagriSema versus placebo: Change in waist circumference | Measured in centimeters (cm) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in systolic blood pressure (SBP) | Measured in millimeters of mercury (mmHg) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score | Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning Score | Measured as score points. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo, semaglutide and cagrilintide: Change in body weight | Measured in kilograms (kg) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI) | Measured in kilogram per square meter (kg/m^2) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo, semaglutide and cagrilintide: Improvement in weight category | Measured as count of participants. The categories are: BMI, underweight less than (<) 18.5, normal weight 18.5 to <25, overweight 25.0 to <30, obesity class I 30 to < 35, obesity class II 35 to < 40, obesity class III >40. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in Glycated Haemoglobin (HbA1c) | Measured as percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in HbA1c | Measured as millimoles per mole (mmol/mol). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in Fasting Plasma Glucose (FPG) (mmol/L). | Measured as millimoles per liter (mmol/L). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in FPG (mg/dL) | Measured as milligrams per deciliter (mg/dL). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in fasting serum insulin | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in Diastolic Blood Pressure (DBP) | Measured in mmHg | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in total cholesterol | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in High-density lipoprotein (HDL) cholesterol | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in Low-density lipoprotein (LDL) cholesterol | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in Very low-density lipoprotein (VLDL) cholesterol | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in Triglycerides | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Ratio to baseline in Free fatty acids | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Change in waist circumference | Measured in centimeters (cm) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Change in SBP | Measured in mmHg | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Ratio to baseline in total cholesterol | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Ratio to baseline in HDL | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Ratio to baseline in LDL | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Ratio to baseline in VLDL | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Triglycerides | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Free fatty acids | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Relative change in body weight (Measured in kilograms (kg)) | Measured in kilograms (kg). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Relative change in body weight (Measured in percentage (%)) | Measured in percentage (%). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Absolute change in body weight (Measured in kilograms (kg)) | Measured in kilograms (kg). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Absolute change in body weight (Measured in percentage (%)) | Measured in percentage (%). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as kilograms (kg)) | Measured as kilograms (kg) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as percentage (%)) | Measured as percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as kilograms (kg)) | Measured as kilograms (kg) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as percentage (%)) | Measured as percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as percentage (%)) | Measured as percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as %-points) | Measured as %-points | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as percentage (%)) | Measured as percentage (%). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as %-points) | Measured as %-points | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in kilograms (kg)) | Measured in kilograms (kg) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in percentage (%)) | Measured in percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in kilograms (kg)) | Measured in kilograms (kg) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in percentage (%)) | Measured in percentage (%) | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Achievement of at least 14.6- point increase (yes/no) in IWQOL-Lite-CT Physical Function score | Measured as count of participants. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Physical Functioning score | Measured as count of participants. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in IWQOL-Lite-CT - Physical Function Score | Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in IWQOL-Lite-CT - Psychosocial Score | Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo: Change in IWQOL-Lite-CT - Total Score | Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. | From baseline (week 0) to end of treatment (week 68) |
| Change in Control of Eating (COEQ): Craving Control Score | Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). | From baseline (week 0) to end of treatment (week 68) |
| Change in COEQ: Craving for Savoury food score | Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). | From baseline (week 0) to end of treatment (week 68) |
| Change in COEQ: Hunger score | Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). | From baseline (week 0) to end of treatment (week 68) |
| Change in COEQ: Craving for Sweets Score | Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). | From baseline (week 0) to end of treatment (week 68) |
| Change in COEQ: Positive Mood score | Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). | From baseline (week 0) to end of treatment (week 68) |
| Change in COEQ: Satiety score | Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Change in IWQOL-Lite-CT Physical Function score | Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score | Measured as count of participants. | From baseline (week 0) to end of treatment (week 68) |
| CagriSema versus placebo, semalutide and cagrilintide: Ratio to baseline C-reactive protein (CRP) | Measured as ratio | From baseline (week 0) to end of treatment (week 68) |
| Number of Treatment Emergent Adverse Events (TEAEs) | Measured as count of events | From baseline (week 0) to end of study-main part (week 75) |
| Number of Treatment Emergent Serious adverse events (TESAEs) | Measured as count of events. | From baseline (week 0) to end of study-main part (week 75) |
| Los Angeles |
| California |
| 90017 |
| United States |
| Velocity Clin Res Wstlke | Los Angeles | California | 90057 | United States |
| Univ of Colorado at Denver | Aurora | Colorado | 80045 | United States |
| OptumCare Clinical Trials LLC | Golden | Colorado | 80401 | United States |
| Northeast Research Institute | Fleming Island | Florida | 92003 | United States |
| South Broward Research LLC | Miramar | Florida | 33027 | United States |
| Clinical Neuroscience Solution | Orlando | Florida | 32801 | United States |
| Florida Inst For Clin Res | Orlando | Florida | 32825 | United States |
| Clinical Trial Res Assoc,Inc | Plantation | Florida | 33324 | United States |
| Hope Clin Res & Wellness | Conyers | Georgia | 30094 | United States |
| East West Med Res Inst | Honolulu | Hawaii | 96814 | United States |
| Great Lakes Clinical Trials | Chicago | Illinois | 60640 | United States |
| Endeavor Health | Skokie | Illinois | 60077 | United States |
| Evanston Premier Hlthcr Res | Skokie | Illinois | 60077 | United States |
| Midwest Inst For Clin Res | Indianapolis | Indiana | 46260 | United States |
| Northern Pines Hlth Ctr, PC | Buckley | Michigan | 49620 | United States |
| StudyMetrix Research LLC | City of Saint Peters | Missouri | 63303 | United States |
| Velocity Clinical Research Binghamton | Binghamton | New York | 13905 | United States |
| Comprehensive Weight Ctrl Prog | New York | New York | 10021 | United States |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | United States |
| University of North Carolina | Chapel Hill | North Carolina | 27517 | United States |
| Medication Mgmnt, LLC_Grnsboro | Greensboro | North Carolina | 27405 | United States |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | United States |
| Accellacare_NC | Raleigh | North Carolina | 27609 | United States |
| Accellacare | Wilmington | North Carolina | 28401 | United States |
| New Venture Medical Research | Wadsworth | Ohio | 44281 | United States |
| Lynn Institute of Norman | Norman | Oklahoma | 73072 | United States |
| The University of Penn Center | Philadelphia | Pennsylvania | 19104-3317 | United States |
| Clinical Res Collaborative | Cumberland | Rhode Island | 02864 | United States |
| Medical Uni of SC Charleston | Charleston | South Carolina | 29425 | United States |
| Coastal Carolina Res Ctr | North Charleston | South Carolina | 29405 | United States |
| Hillcrest Clinical Research | Simpsonville | South Carolina | 29681-1538 | United States |
| Spartanburg Medical Research | Spartanburg | South Carolina | 29303 | United States |
| Holston Medical Group_Bristol | Bristol | Tennessee | 37620 | United States |
| Holston Medical Group | Kingsport | Tennessee | 37660 | United States |
| Baylr Sctt White Rs Inst, Endo | Dallas | Texas | 75226 | United States |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | United States |
| UT Southwestern Med Cntr | Dallas | Texas | 75390-9302 | United States |
| DCOL Ctr for Clin Res | Longview | Texas | 75605 | United States |
| Washington Cntr Weight Mgmt | Arlington | Virginia | 22206 | United States |
| Health Res of Hampton Roads | Newport News | Virginia | 23606 | United States |
| Selma Medical Associates | Winchester | Virginia | 22601-3834 | United States |
| Capital Clin Res Ctr,LLC | Olympia | Washington | 98502 | United States |
| Rainier Clin Res Ctr Inc | Renton | Washington | 98057 | United States |
| Fundación CESIM | Santa Rosa | La Pampa Province | 6300 | Argentina |
| CEDIC Centro de Investigación Clínica | CABA | C1060ABA | Argentina |
| Centro de Investigación Clínica | CABA | C1060ABA | Argentina |
| Centro Médico Viamonte SRL | CABA | C1120AAC | Argentina |
| Instituto Centenario | Ciudad de Buenos Aires | C1204AAD | Argentina |
| Sanatorio Norte | Santiago del Estero | G4200 | Argentina |
| Northern Beaches Clinical Research | Brookvale | New South Wales | 2100 | Australia |
| Novatrials | Charlestown | New South Wales | 2290 | Australia |
| Momentum Clinical Research Darlinghurst | Darlinghurst | New South Wales | 2010 | Australia |
| Momentum Clinical Research Taringa | Taringa | Queensland | 4068 | Australia |
| Imeldaziekenhuis - Bonheiden - Department of Endocrinology | Bonheiden | 2820 | Belgium |
| CHR Mons-Hainaut - Site Warquignies | Boussu | 7300 | Belgium |
| Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie | Brussels | 1200 | Belgium |
| UZ Antwerpen - UZA - Department of Endocrinology | Edegem | 2650 | Belgium |
| UZA - UZ Antwerpen - Department of Endocrinology | Edegem | 2650 | Belgium |
| UZ Gent - Endocrinologie | Ghent | 9000 | Belgium |
| UZ Leuven - Endocrinology | Leuven | 3000 | Belgium |
| CHU Helora - Hôpital de Mons - Site Constantinople | Mons | 7000 | Belgium |
| Medical centre Asclepius OOD | Dupnitsa | Kyustendil | 2600 | Bulgaria |
| MHAT Puls AD, Department of Internal Diseases | Blagoevgrad | 2700 | Bulgaria |
| OCIPSOMC - Endocrinology NT EOOD | Montana | 3400 | Bulgaria |
| OCSOMCE - Dr. Albena Dinkova EOOD | Pleven | 5800 | Bulgaria |
| DCC Iztok EOOD | Plovdiv | 4006 | Bulgaria |
| ASOMCEM - Individual Practice - Dr. Antoanela Slavcheva | Rousse | 7002 | Bulgaria |
| ASOMCEM - IP - Dr. Antoanela Slavcheva | Rousse | 7002 | Bulgaria |
| Nader Yabrudi - ASMPVBE Individual practice | Smolyan | 4700 | Bulgaria |
| UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases | Sofia | 1431 | Bulgaria |
| USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology | Sofia | 1431 | Bulgaria |
| USHATE Acad. Ivan Penchev EAD, First Clinic of Endocrinology | Sofia | 1431 | Bulgaria |
| USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology | Sofia | 1431 | Bulgaria |
| DCC XVIII - Sofia EOOD | Sofia | 1517 | Bulgaria |
| UMHAT Tsaritsa Yoanna - ISUL EAD, Endocrinology | Sofia | 1527 | Bulgaria |
| DCC XX - Sofia EOOD, Endocrinology | Sofia | 1618 | Bulgaria |
| AIPSMC Dr. Artin Magardichyan EOOD | Varna | 9020 | Bulgaria |
| MC Berbatov EOOD, Cherni Drin | Yambol | 8600 | Bulgaria |
| C-endo Diab & Endo Clinic | Edmonton | Alberta | T6H 2L4 | Canada |
| Synergy Wellness Clinic | Sherwood Park | Alberta | T8H 0N2 | Canada |
| Ocean West Research Clinic | Surrey | British Columbia | V3Z 2N6 | Canada |
| Dr. M.B. Jones Inc | Victoria | British Columbia | V8V 4A1 | Canada |
| G.A. Research Associates Ltd. | Moncton | New Brunswick | E1G 1A7 | Canada |
| Nova Scotia Hlth Halifax | Halifax | Nova Scotia | B3H 1V7 | Canada |
| Premier Clinical Trial Research Network (PCTRN) | Hamilton | Ontario | L8M 1K7 | Canada |
| Sjællands Universitetshospital, Køge - Medicinsk Afdeling | Køge | Region Sjælland | 4600 | Denmark |
| Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden | Esbjerg | Region Syddanmark | 6700 | Denmark |
| Aarhus Universitetshospital Diabetes og Hormonsygdomme | Aarhus N | 8200 | Denmark |
| Center for Klinisk Metabolisk Forskning | Hellerup | 2900 | Denmark |
| Gentofte Hospital - Center for Klinisk Metabolisk Forskning | Hellerup | 2900 | Denmark |
| Hvidovre Hospital Endokrinologisk forsknings afsnit 159 | Hvidovre | 2650 | Denmark |
| Sjællands Universitetshospital | Køge | 4600 | Denmark |
| HUS Clinical Research Obesity Unit CRC | Helsinki | 00290 | Finland |
| Health Step Finland Oy | Kuopio | 70600 | Finland |
| OYS - Sisätautien tutkimusyksikkö | Oulu | 90220 | Finland |
| Turku University Hospital | Turku | 20520 | Finland |
| APHP - LA PITIE SALPETRIERE _ Service de Nutrition | Paris | 75013 | France |
| Hospices Civils de Lyon-Hopital Lyon Sud | Pierre-Bénite | 69310 | France |
| Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec | Saint-Herblain | 44800 | France |
| Les Hopitaux Universitaires de Strasbourg-Hopital de Hautepierre | Strasbourg | 67098 | France |
| Centre de Recherche Clinique Portes Du Sud | Vénissieux | 69200 | France |
| Diabetespraxis Mergentheim | Bad Mergentheim | 97980 | Germany |
| Zentrum für klinische Studien Südbrandenburg GmbH | Elsterwerda | 04910 | Germany |
| InnoDiab Forschung GmbH | Essen | 45136 | Germany |
| Wendisch - Dahl Hamburg - DZHW | Hamburg | 22607 | Germany |
| Uniklinik Leipzig - Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie | Leipzig | 04103 | Germany |
| AmBeNet GmbH | Leipzig | 04107 | Germany |
| Institut für Diabetesforschung GmbH Münster - Dr. med. Rose | Münster | 48145 | Germany |
| MZM Praxis Drs. Erlinger | Stuttgart | 70378 | Germany |
| Zentrum für klinische Studien Allgäu Oberschwaben | Wangen | 88239 | Germany |
| Nirmal Hospital Pvt. Ltd. | Surat | Gujarat | 395002 | India |
| Belgaum Diabetes Centre | Belagavi | Karnataka | 590001 | India |
| Government Medical College, Kozhikode | Kozhikode | Kerala | 673008 | India |
| Sir H. N. Reliance Foundation Hospital and Research Centre | Mumbai | Maharashtra | 400004 | India |
| Wockhardt Hospital, Mumbai Central | Mumbai | Maharashtra | 400011 | India |
| Government Medical College and Super Speciality Hospital, Nagpur | Nagpur | Maharashtra | 440009 | India |
| Grant Medical Foundation Ruby Hall Clinic | Pune | Maharashtra | 411001 | India |
| Deenanath Mangeshkar Hospital & Research Centre | Pune | Maharashtra | 411004 | India |
| Sahyadri Super Speciality Hospital | Pune | Maharashtra | 411004 | India |
| Chellaram Diabetes Institute | Pune | Maharashtra | 411021 | India |
| chelleram Diabetes Institute | Pune | Maharashtra | 411021 | India |
| Maulana Azad Medical College | Delhi | New Delhi | 110002 | India |
| Post Graduate Institute of Medical Education & Research_Chandigarh | Chandigarh | Punjab | 160012 | India |
| SMS Medical College & Hospital | Jaipur | Rajasthan | 302004 | India |
| Eternal Heart Care Centre | Jaipur | Rajasthan | 302017 | India |
| Christian Medical College Hospital, Vellore | Vellore | Tamil Nadu | 632004 | India |
| AIG Hospitals,Hyderabad | Hyderabad | Telangana | 500032 | India |
| All India Institute of Medical Sciences_New Dehli | Delhi | 110029 | India |
| Osmania General Hospital | Hyderabad | 500012 | India |
| A.O.U. Consorziale Policlinico di Bari | Bari | BA | 70124 | Italy |
| Azienda Ospedaliero-Universitaria Renato Dulbecco | Catanzaro | Cz | 88100 | Italy |
| Policlinico San Donato S.p.A. | San Donato Milanese (MI) | Lombardy | 20097 | Italy |
| Pol. Uni. Campus Biomedico | Roma | RM | 00128 | Italy |
| Azienda Ospedaliera Universitaria Senese | Siena | SI | 53100 | Italy |
| A.O.Universitaria S.ORSOLA-MALPIGHI - U.O.Endocrinologia e Cura | Bologna | 40138 | Italy |
| ARNAS Garibaldi Catania - Presidio Ospedaliero Garibaldi-Centro | Catania | 95122 | Italy |
| Azienda Ospedaliera di Padova Clin.Med.3 | Padova | 35128 | Italy |
| Ospedale Civico Partinico di Palermo | Partinico | 90047 | Italy |
| Policlinico Universitario Tor Vergata | Roma | 00133 | Italy |
| AOU Policlinico Umberto I - Dip. Medicina Interna, Scienze endocrino-metaboliche e malattie infettive | Roma | 00161 | Italy |
| Shinsapporo Seiryou Hospital_General Clinical Department | Sapporo | Hokkaido | 004-0004 | Japan |
| OCROM Clinic_Internal medicine | Suita-shi | Osaka | 565-0853 | Japan |
| TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology | Aichi | 468-0009 | Japan |
| Chiba University Hospital_Diabetes, Metabolism and Endocrinology | Chiba-shi, Chiba | 260-8677 | Japan |
| Kawada Clinic | Gunma | 373-0036 | Japan |
| Motomachi Takatsuka Naika Clinic_Internal Medicine | Kanagawa | 231-0023 | Japan |
| Osaka NISHI-UMEDA Clinic_Internal Medicine | Osaka | 530-0001 | Japan |
| Asano Clinic | Saitama | 350-0851 | Japan |
| Shinden Higashi Clinic_Internal medicine | Sendai-shi, Miyagi | 983-0039 | Japan |
| Tokyo-Eki Center-building Clinic_Internal Medicine | Tokyo | 103-0027 | Japan |
| Tokyo-Eki Center-building Clinic | Tokyo | 103-0027 | Japan |
| Fukuwa Clinic_Internal Medicine | Tokyo | 104-0031 | Japan |
| Miho Clinic | Tokyo | 141-0032 | Japan |
| ToCROM Clinic_Internal Medicine | Tokyo | 160-0008 | Japan |
| Higashi-shinjuku clinic | Tokyo | 169-0072 | Japan |
| Consultorio Arechavaleta Granell María del Rosario | Guadalajara | Jalisco | 44650 | Mexico |
| Centro de Investigacion Clinica Endocrinologica de Jalisco | Guadalajara | Jalisco | 44670 | Mexico |
| Internal Medicine Clin Trials | Monterrey | Nuevo León | 64020 | Mexico |
| Cardiolink Clin Trials S.C. | Monterrey | Nuevo León | 64060 | Mexico |
| Centro de Investigación Cardiometabólica de Aguascalientes | Aguascalientes | 20230 | Mexico |
| AmsterdamUMC AMC | Amsterdam | 1105 AZ | Netherlands |
| Rijnstate Ziekenhuis | Arnhem | 6815 AD | Netherlands |
| Spaarne Gasthuis Hoofddorp - Interne | Hoofddorp | 2134 TM | Netherlands |
| Bravis Zkh Roosendaal | Roosendaal | 4708 AE | Netherlands |
| Albert Schweitzer Zkh, Zwijndrecht - Interne | Zwijndrecht | 3331 LZ | Netherlands |
| 50BIO.COM Sp. z o.o. | Bydgoszcz | Kujawsko-Pomorskie Voivodeship | 85-107 | Poland |
| Gierach-Med | Bygdoszcz | Kuyavian-Pomeranian Voivodeship | 85-796 | Poland |
| Centrum Medyczne Plejady | Krakow | Lesser Poland Voivodeship | 30-363 | Poland |
| Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j. | Legnica | Lower Silesian Voivodeship | 59-220 | Poland |
| Terpa Sp. z o.o. Sp. k. | Lublin | Lubelskie Voivodeship | 20-333 | Poland |
| Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orlowskiego Centrum Medycznego Ksztalcenia Podyplomowego | Warsaw | Masovian Voivodeship | 00-416 | Poland |
| Instytut Diabetologii Sp. z o.o. | Warsaw | Mazovian Voivodeship | 02-117 | Poland |
| Uniwersytecki Szpital Kliniczny w Bialymstoku | Bialystok | Podlaskie Voivodeship | 15-276 | Poland |
| Gabinet Leczenia Otylosci i Chorob Dietozaleznych | Bialystok | Podlaskie Voivodeship | 15-281 | Poland |
| NZOZ Vita-Diabetica Malgorzata Buraczyk | Bialystok | Podlaskie Voivodeship | 15-879 | Poland |
| Uniwersyteckie Centrum Kliniczne | Gdansk | Pomeranian Voivodeship | 80-214 | Poland |
| Centrum Medyczne Salvia | Katowice | Slaskie Voivodeship | 40-772 | Poland |
| Klinika Bellamed | Elblag | Warmian-Masurian Voivodeship | 82-300 | Poland |
| Centrum Ginekologii, Poloznictwa i Leczenia Nieplodnosci | Poznan | Wielkopolskie Voivodeship | 60-198 | Poland |
| Centrum Ginekologii, Położnictwa i Leczenia Niepłodności | Poznan | Wielkopolskie Voivodeship | 60-198 | Poland |
| Centrum Zdrowia Metabolicznego Paweł Bogdański | Poznan | Wielkopolskie Voivodeship | 60-589 | Poland |
| Centrum Medyczne Plejady | Krakow | 30-363 | Poland |
| Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j. | Legnica | 59-220 | Poland |
| Terpa Sp. z o.o. Sp. k. | Lublin | 20-333 | Poland |
| Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego | Warsaw | 00-416 | Poland |
| Instytut Diabetologii Sp. z o.o. | Warsaw | 02-117 | Poland |
| Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis. | Novi Sad | Vojvodina | 21000 | Serbia |
| Endocrinology, Diabetes and Metabolism Diseases Clinic | Belgrade | 11000 | Serbia |
| Clinical Hospital Center Bezanijska Kosa | Belgrade | 11080 | Serbia |
| Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis. | Novi Sad | 21000 | Serbia |
| East Rand Physicians | Benoni | Gauteng | 1501 | South Africa |
| Dr R Dulabh | Johannesburg | Gauteng | 1812 | South Africa |
| Dr Moosa's Rooms | Lenasia | Gauteng | 1827 | South Africa |
| Shop#1 Health Emporium | Midrand | Gauteng | 1685 | South Africa |
| Botho ke Bontle Health Services | Pretoria | Gauteng | 0184 | South Africa |
| Dr Vawda's site | Durban | KwaZulu-Natal | 4091 | South Africa |
| Dr J Reddy | Durban | KwaZulu-Natal | 4450 | South Africa |
| Armansis Medical Centre | Brits | North West | 0250 | South Africa |
| Dr Hilton Kaplan | Cape Town | Western Cape | 7708 | South Africa |
| The Catholic University of Korea, Bucheon ST. Mary's Hospital | Bucheon-si | Gyeonggi-do | 14647 | South Korea |
| The catholic university of Korea, Bucheon St.Mary's Hospital | Bucheon-si | Gyeonggi-do | 14647 | South Korea |
| Seoul National University Bundang Hospital | Seongnam-si | Gyeonggi-do | 13620 | South Korea |
| Pusan National University Yangsan Hospital | Yangsan | Gyeongsangnam-do | 50612 | South Korea |
| Kyungpook National University Hospital | Daegu | 14233 | South Korea |
| Daejeon Eulji Medical Center, Eulji University | Daejeon | 35233 | South Korea |
| Gachon University Gil Medical Center | Incheon | 21565 | South Korea |
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do | 13620 | South Korea |
| Seoul National University Hospital | Seoul | 03080 | South Korea |
| Severance Hospital, Yonsei University Health System | Seoul | 03722 | South Korea |
| Asan Medical Center | Seoul | 05505 | South Korea |
| Samsung Medical Center | Seoul | 06351 | South Korea |
| Pusan National University Yangsan Hospital | Yangsan | 50612 | South Korea |
| Clinica Universitaria de Navarra | Pamplona | Navarre | 31008 | Spain |
| Hospital Clinic i Provincial | Barcelona | 08036 | Spain |
| Hospital Vithas Sevilla | Castilleja de la Cuesta | 41950 | Spain |
| H. de León_Endocrinología | León | 24008 | Spain |
| Hospital de León | León | 24008 | Spain |
| Hospital Gregorio Marañón | Madrid | 28007 | Spain |
| Clínica Nuevas Tecnologías en Diabetes y Endocrinología | Seville | 41003 | Spain |
| H. Infanta Luisa_Endocrino y Obesidad | Seville | 41010 | Spain |
| China Medical University Hospital | Taichung | 404 | Taiwan |
| National Taiwan University Hospital_main | Taipei | 100 | Taiwan |
| Baskent University Ankara Hospital | Ankara | Cankaya | 06800 | Turkey (Türkiye) |
| Başkent Üniversitesi Ankara Hastanesi-Aile Hekimliği | Ankara | Cankaya | 06800 | Turkey (Türkiye) |
| Haseki Egitim ve Arastirma Hastanesi | Sultangazi | Istanbul | 34265 | Turkey (Türkiye) |
| Adana Şehir Eğitim ve Araştırma Hastanesi | Adana | 01060 | Turkey (Türkiye) |
| Başkent Üniversitesi Adana Dr. Turgut Noyan Uygulama ve Araştırma Merkezi | Adana | 01250 | Turkey (Türkiye) |
| Ankara Bilkent Şehir Hastanesi-Dahiliye | Ankara | 06800 | Turkey (Türkiye) |
| Ankara Sehir Hastanesi Dahiliye Klinigi | Ankara | 06800 | Turkey (Türkiye) |
| Akdeniz Üniversitesi Hastanesi- Endokrinoloji | Antalya | 07058 | Turkey (Türkiye) |
| Hatay Mustafa Kemal Universitesi Saglik Uygulama ve Arastirm | Hatay | 31060 | Turkey (Türkiye) |
| Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji | Istanbul | 34390 | Turkey (Türkiye) |
| İstanbul Üniversitesi İstanbul Tıp Fakültesi Hastanesi- Endokrinoloji | Istanbul | 34390 | Turkey (Türkiye) |
| Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi- Endokrinoloji | Istanbul | 34400 | Turkey (Türkiye) |
| Haydarpaşa Numune Eğitim ve Araştırma Hastanesi - Endokrinoloji | Istanbul | 34668 | Turkey (Türkiye) |
| Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye | Istanbul | 34722 | Turkey (Türkiye) |
| Sivas Cumhuriyet Univesity Endocrinology Department | Sivas | 58140 | Turkey (Türkiye) |
| Sivas Cumhuriyet Üniversitesi Hastanesi -Endokrinoloji | Sivas | 58140 | Turkey (Türkiye) |
| Princess Royal University Hospital | Orpington | Kent | BR6 8ND | United Kingdom |
| Layton Medical Centre | Blackpool | FY3 7EN | United Kingdom |
| Southmead Hospital | Bristol | BS10 5NB | United Kingdom |
| Addenbrooke's Hospital_Cambridge | Cambridge | CB2 0QQ | United Kingdom |
| Countess of Chester Hospital | Chester | CH2 1UL | United Kingdom |
| Hathaway Medical Centre | Chippenham | SN14 6GT | United Kingdom |
| University Hospital Coventry - WISDEM Centre | Coventry | CV2 2DX | United Kingdom |
| Aintree University Hospital | Liverpool | L9 7AL | United Kingdom |
| University Hospital Aintree | Liverpool | L9 7AL | United Kingdom |
| Guy's Hospital - Diabetes | London | SE1 9RT | United Kingdom |
| Imperial College London | London | W12 0HS | United Kingdom |
| University College London - Obesity | London | WC1E 6JF | United Kingdom |
| Princess Royal University Hospital | Orpington | BR6 8ND | United Kingdom |
| Musgrove Park Hospital | Taunton | TA1 5DA | United Kingdom |
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000717792 | cagrilintide |
| C000591245 | semaglutide |
Not provided
Not provided
Not provided